Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBITDA Margin across 17 years of filings, most recently posting 68.14% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 68.14%, up 13889.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.19% (up 1551.0% YoY), and the FY2025 annual result was 4.97%, down 2153.0% from the prior year.
• EBITDA Margin came in at 68.14% for Q1 2026 at Ironwood Pharmaceuticals, up from 161.38% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 68.14% in Q1 2026 to a low of 989.17% in Q2 2023.
• The 5-year median for EBITDA Margin is 35.19% (2023), against an average of 38.43%.
• Across the five-year window, EBITDA Margin tumbled 102730 bps in 2023 and jumped 101563 bps in 2024, its largest moves.
• Ironwood Pharmaceuticals' EBITDA Margin stood at 45.59% in 2022, then decreased by 30 bps to 31.98% in 2023, then gained by 9 bps to 34.78% in 2024, then tumbled by 564 bps to 161.38% in 2025, then surged by 142 bps to 68.14% in 2026.
• The last three EBITDA Margin figures came in at 68.14% (Q1 2026), 161.38% (Q4 2025), and 61.84% (Q3 2025), per Business Quant data.